Sells cell-engineering instruments, single-use processing assemblies and consumables to cell therapy developers, biopharmaceutical companies and research institutions.
10-K for FY2025, filed Mar 25, 2026Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell…View ↗
From leading commercial cell therapy drug and biologic developers and top biopharmaceutical companies to top academic and government…View ↗
We believe the current ExPERT instrument family represents the next generation of our clinically validated electroporation technology for…View ↗
Revenue is principally from the sale of instruments, PAs and consumables, assay services, and extended warranties and from our license…View ↗
Customers buy instruments, processing assemblies, consumables and assay services; instrument license fees cover the license term. SPL customers may also owe payments when programs reach development milestones and sales-based payments on commercialized therapies.
10-K for FY2025, filed Mar 25, 2026Revenue is principally from the sale of instruments, PAs and consumables, assay services, and extended warranties and from our license…View ↗
Licensing fee revenue for licenses of symbolic intellectual property is recognized ratably over the license period as a single performance…View ↗
Some of these licensing arrangements include provisions for milestone payments to the Company, if the customer accomplishes certain…View ↗
Our SPL customers typically pay an annual license fee per instrument per year for a research license (for preclinical use) or per…View ↗
10-K for FY2025, filed Mar 25, 2026
FY2025 revenue by product or service ↗$33M
10-K for FY2025, filed Mar 25, 2026
$33M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales
Sold outright
10-K for FY2025, filed Mar 25, 2026 |
57%
FY2022: 63%
|
Product sales, FY2025
$18.7M Sources
|
Sold outright |
|
Licenses
Recurring
10-K for FY2025, filed Mar 25, 2026 |
37% |
Licenses, FY2025
$12.4M Sources
|
Recurring |
|
Assay and other service revenue
Sold outright
|
6.0% |
Assay and other service revenue, FY2025
$2M Sources
|
Sold outright |
Cell therapy developers, biopharmaceutical and biotechnology companies, and academic and government research institutions use the platform. MaxCyte sells instruments to research users and licenses them to academic and commercial customers for research or clinical work.
10-K for FY2025, filed Mar 25, 2026From leading commercial cell therapy drug and biologic developers and top biopharmaceutical companies to top academic and government…View ↗
Our sales model varies based on the activity of the end customer, such as whether they are a translational research center, an academic…View ↗
Research licenses are agreements with academic institutions or commercial entities which provide access to the use of our instruments for…View ↗
Clinical licenses are agreements with academic institutions or commercial entities that provide access to the use of our instruments for…View ↗
Given our value proposition in non-viral delivery, we have established strategic relationships in the form of SPL agreements with a growing…View ↗
10-K for FY2025, filed Mar 25, 2026
Significant customers are those that accounted for 10% or more of the Company’s total revenue for the period or accounts receivable as the…View ↗
No. It lost $44.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$4.8MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Oct 14, 2026
Full year revenue expected to be approximately $34 million, compared to prior guidance of $30 million to $32 million, consisting of:View ↗
8-K, filed Aug 12, 2026
Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in JulyView ↗
8-K, filed Mar 27, 2026
On March 23, 2026, the Board of Directors (the “Board”) of MaxCyte, Inc. (the “Company”) appointed Parmeet Ahuja as the Company’s Chief…View ↗
Flat. Revenue was $33M in FY2025, about the same as the $33.9M of FY2021.
Added a discovery instrument
The latest report describes DTx for discovery among the ExPERT instruments, while the older report listed the ATx, STx, GTx and VLx.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 25, 2026Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell…View ↗
Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell…View ↗
Expanded gene-editing assessment services
The latest report describes SeQure's gene-editing assessment services alongside MaxCyte's electroporation platform; the acquisition expanded services for cell and gene therapy developers.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 25, 2026We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery…View ↗
In January 2025, we acquired SeQure Dx, (“SeQure”) a market leader for on-target and off-target editing assessment services for cell and…View ↗
Loading...